350 rub
Journal Technologies of Living Systems №9 for 2012 г.
Article in number:
Novel glucocorticoid receptor ligands: modified steroids and non-steroids selective agonists
Keywords: modified steroids glucocorticoid receptor transactivation transrepression selective glucocorticoid receptor agonists
Authors:
E.A. Lesovaya, K.I. Kirsanov, G.A. Belitsky, I.V. Budunova, M.G. Yakubovskaya
Abstract:
Clucocorticoids (GC) present the classical anti-inflammatory, antiproliferative and immunomodulating compounds. Specific cytotoxic effect in lymphoid cells these hormones are widely used in the chemotherapy of hematopoetic malignancies. High doses of glucocorticoids are necessary to decrease the number of leukocytes and lymphocytes in the acute phase of disease and to effectively induce remission. Successful remission consolidation requires glucocorticoid treatment in lower dosage as well. However, the chronic treatment with GC can also lead to a number of metabolic complications (such as osteoporosis, diabetes, Ichenko-Kushing syndrome, water-salt metabolism imbalance etc), which limit the GC usage in clinic. Thus, the development of the new glucocorticoid receptor (GR) ligands with improved therapeutic index and decreased side effects is of a great importance nowadays. Such compounds could be a better alternative to the standard GC during the treatment of patients with hematological malignancies as well as many other diseases.
Pages: 27-32
References
  1. Adcock I.M. Molecular mechanisms of glucocorticosteroid actions // Pulm. Pharmacol. Ther. 2000. V. 13. №3. P. 115 - 126.
  2. Barnes P.J., Adcock I.M. Glucocorticoid resistance in inflammatory diseases // Lancet. 2009. V. 373. №9678. P. 1905 - 1917.
  3. Gross K.L., Lu N.Z., Cidlowski J.A. Molecular mechanisms regulating glucocorticoid sensitivity and resistance // Mol. Cell Endocrinol. 2009.  V. 300. №1 - 2. P. 7 - 16.
  4. Irving J.A., Minto L., Bailey S., Hall A.G. Loss of heterozygosity and somatic mutations of the glucocorticoid receptor gene are rarely found at relapse in pediatric acute lymphoblastic leukemia but may occur in a subpopulation early in the disease course // Cancer Res. 2005. V. 65.№ 21. P. 9712 - 9718.
  5. RuizM.,LindU.,Gåfvels M.,Eggertsen G.,Carlstedt-Duke J.,Nilsson L.,Holtmann M.,Stierna P.,Wikström A.C.,Werner S. Characterization of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance //Clin.Endocrinol. 2001. V. 55. № 3. P. 363 - 371.
  6. Smith L.K., Cidlowski J.A. Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes // Prog. Brain Res. 2010. V. 182. P. 1 - 30.
  7. Miner J.N., Hong M.H., Negro-Vilar A. New and improved glucocorticoid receptor ligands // Expert. Opin. Investig. Drugs. 2005. V. 14. № 12. P. 1527 - 1545.
  8. Katsumata M.,Gupta C.,Baker M.K.,Sussdorf C.E.,Goldman A.S. Diphenylhydantoin: an alternative ligand of a glucocorticoid receptor affecting prostaglandin generation in A/J mice // Science. 1982. V. 218. №4579. P. 1313 - 1315.
  9. Schmidt S., Irving J.A., Minto L.,Matheson E., Nicholson L., Ploner A.,Parson W., Kofler A.,Amort M.,Erdel M.,Hall A., Kofler R.Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor // FASEB J. 2006. V. 20. №14. P. 2600 - 2602.
  10. Paul-Clark M.J., Gilroy D.W., Willis D., Willoughby D.A., Tomlinson A. Nitric oxide synthase inhibitors have opposite effects on acute inflammation depending on their route of administration // J. Immunol. 2001. V. 166. №2. P. 1169 - 1177.
  11. Vayssière B.M.,Dupont S.,Choquart A.,Petit F.,Garcia T.,Marchandeau C.,Gronemeyer H.,Resche-Rigon M. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo// Mol. Endocrinol. 1997. V. 11. №9. P. 1245 - 1255.
  12. Schacke H., Rehwinkel H. Dissociated glucocorticoid receptor ligands // Curr. Opin. Investig. Drugs. 2004. V. 5. №5. P. 524 - 528.
  13. Schacke H., Rehwinkel H., Asadullah K., Cato A.C.Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index // Exp. Dermatol. 2006. V. 15. № 8. P. 565 - 573.
  14. Lin C.W., Nakane M., Stashko M. Trans-acti­vation and repression properties of the novel non-steroid glucocorticoid receptor ligand
    2,5-dihydro-9-hydroxy-10-methoxy-2,2,4-trime­thyl-5-(1-methylcyclohexen-3-y1)-1H-[1]benzo­pyrano[3,4-f]quinoline (A276575) and its four stereoisomers // Mol. Pharmacol. 2002. V. 62. №2. P. 297 - 303.
  15. Humphrey E.L., Williams J.H., Davie M.W., Marshall M.J.Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells // Bone. 2005. V. 38. № 5. P. 652 - 661.
  16. http://www.clinicaltrials.gov/
  17. Cavet M.E., Harrington K.L., Ward K.W., Zhang J.Z.
    Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells // Mol. Vis. 2010. V. 16. P. 1791 - 1800.
  18. Swart P., Swart A.C., Louw A., van der Merwe K.J. Biological activities of the shrub Salsola tuberculatiformis Botsch.: contraceptive or stress alleviator - // Bioassays. 2003. V. 25. №6. P. 612 - 619.
  19. De Bosscher K., Haegeman G., Elewaut D. Targeting inflammation using selective glucocorticoid receptor modulators // Curr. Opin. Pharmacol. 2010. V. 10. №4. P. 497 - 504.
  20. De Bosscher K., Vanden Berghe W., Beck I.M., Van Molle W., Hennuyer N., Hapgood J., Libert C., Staels B., Louw A., Haegeman G. A fully dissociated compound of plant origin for inflammatory gene repression // Proc. Natl. Acad. Sci. USA. 2005. V. 102. №44. P. 15827 - 15832.
  21. Yemelyanov A., Czwornog J., Gera L., Joshi S., Chatterton R.T.Jr., Budunova I.Novel steroid receptor phyto-modulator compound A inhibits growth and survival of prostate cancer cells // Cancer Res. 2008. V. 68. № 12. P. 4763 - 4773.
  22. Лесовая Е.А. Емельянов А.Ю., Кирсанов К.И., Якубовская М.Г., Будунова И.В. Противоопухолевое действие нестероидного лиганда глюкокортикоидного рецептора, CpdA, на лейкозные клетки линий СЕМ и К562 // Биохимия (Москва). 2011. Т. 76. № 11. С. 1542 - 1555.
  23. Ronacher K., Hadley K., Avenant C., Stubsrud E., Simons S.S.Jr., Louw A., Hapgood J.P. Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction // Mol. Cell Endocrinol. 2009. V. 299. № 2. P. 219 - 231.